- call +1-201-465-4211
- email sales@mrinsights.biz
The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.
Scope of the Report:
This report focuses on the Pulmonary Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives.
The worldwide market for Pulmonary Drugs is expected to grow at a CAGR of roughly 8.3% over the next five years, will reach 49000 million US$ in 2023, from 30400 million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Sanofi SA
Meda Pharmaceuticals
Circassia Pharmaceuticals Plc.
AstraZeneca Plc.
GlaxoSmithKline Plc.
Mallinckrodt Pharmaceuticals Plc.
Cheisi Farmaceutici S.p.A
Zambon Company S.p.A
Alaxia SAS
Merck Sharp & Dohme Limited
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Others
Market Segment by Applications, can be divided into
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others
There are 15 Chapters to deeply display the global Pulmonary Drugs market.
Chapter 1, to describe Pulmonary Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Pulmonary Drugs, with sales, revenue, and price of Pulmonary Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Pulmonary Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Pulmonary Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Pulmonary Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Pulmonary Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Inhaled Corticosteroids
1.2.2 Long Acting Beta-2 Agonists
1.2.3 Antihistamines
1.2.4 Vasodilators
1.2.5 Others
1.3 Market Analysis by Applications
1.3.1 Asthma & COPD
1.3.2 Allergic Rhinitis
1.3.3 Pulmonary Arterial Hypertension
1.3.4 Cystic Fibrosis
1.3.5 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Sanofi SA
2.1.1 Business Overview
2.1.2 Pulmonary Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Sanofi SA Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Meda Pharmaceuticals
2.2.1 Business Overview
2.2.2 Pulmonary Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Meda Pharmaceuticals Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Circassia Pharmaceuticals Plc.
2.3.1 Business Overview
2.3.2 Pulmonary Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 AstraZeneca Plc.
2.4.1 Business Overview
2.4.2 Pulmonary Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 AstraZeneca Plc. Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 GlaxoSmithKline Plc.
2.5.1 Business Overview
2.5.2 Pulmonary Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 GlaxoSmithKline Plc. Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Mallinckrodt Pharmaceuticals Plc.
2.6.1 Business Overview
2.6.2 Pulmonary Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Cheisi Farmaceutici S.p.A
2.7.1 Business Overview
2.7.2 Pulmonary Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Zambon Company S.p.A
2.8.1 Business Overview
2.8.2 Pulmonary Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Zambon Company S.p.A Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Alaxia SAS
2.9.1 Business Overview
2.9.2 Pulmonary Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Alaxia SAS Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Merck Sharp & Dohme Limited
2.10.1 Business Overview
2.10.2 Pulmonary Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Merck Sharp & Dohme Limited Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Pulmonary Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Pulmonary Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Pulmonary Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Pulmonary Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Pulmonary Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Pulmonary Drugs Market Analysis by Regions
4.1 Global Pulmonary Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Pulmonary Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Pulmonary Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Pulmonary Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Pulmonary Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Pulmonary Drugs Sales and Growth Rate (2013-2018)
4.5 South America Pulmonary Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Pulmonary Drugs Sales and Growth Rate (2013-2018)
5 North America Pulmonary Drugs by Countries
5.1 North America Pulmonary Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Pulmonary Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Pulmonary Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Pulmonary Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Pulmonary Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Pulmonary Drugs Sales and Growth Rate (2013-2018)
6 Europe Pulmonary Drugs by Countries
6.1 Europe Pulmonary Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Pulmonary Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Pulmonary Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Pulmonary Drugs Sales and Growth Rate (2013-2018)
6.3 UK Pulmonary Drugs Sales and Growth Rate (2013-2018)
6.4 France Pulmonary Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Pulmonary Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Pulmonary Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Pulmonary Drugs by Countries
7.1 Asia-Pacific Pulmonary Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Pulmonary Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Pulmonary Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Pulmonary Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Pulmonary Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Pulmonary Drugs Sales and Growth Rate (2013-2018)
7.5 India Pulmonary Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Pulmonary Drugs Sales and Growth Rate (2013-2018)
8 South America Pulmonary Drugs by Countries
8.1 South America Pulmonary Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Pulmonary Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Pulmonary Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Pulmonary Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Pulmonary Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Pulmonary Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Pulmonary Drugs by Countries
9.1 Middle East and Africa Pulmonary Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Pulmonary Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Pulmonary Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Pulmonary Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Pulmonary Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Pulmonary Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Pulmonary Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Pulmonary Drugs Sales and Growth Rate (2013-2018)
10 Global Pulmonary Drugs Market Segment by Type
10.1 Global Pulmonary Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Pulmonary Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Pulmonary Drugs Revenue and Market Share by Type (2013-2018)
10.2 Inhaled Corticosteroids Sales Growth and Price
10.2.1 Global Inhaled Corticosteroids Sales Growth (2013-2018)
10.2.2 Global Inhaled Corticosteroids Price (2013-2018)
10.3 Long Acting Beta-2 Agonists Sales Growth and Price
10.3.1 Global Long Acting Beta-2 Agonists Sales Growth (2013-2018)
10.3.2 Global Long Acting Beta-2 Agonists Price (2013-2018)
10.4 Antihistamines Sales Growth and Price
10.4.1 Global Antihistamines Sales Growth (2013-2018)
10.4.2 Global Antihistamines Price (2013-2018)
10.5 Vasodilators Sales Growth and Price
10.5.1 Global Vasodilators Sales Growth (2013-2018)
10.5.2 Global Vasodilators Price (2013-2018)
10.6 Others Sales Growth and Price
10.6.1 Global Others Sales Growth (2013-2018)
10.6.2 Global Others Price (2013-2018)
11 Global Pulmonary Drugs Market Segment by Application
11.1 Global Pulmonary Drugs Sales Market Share by Application (2013-2018)
11.2 Asthma & COPD Sales Growth (2013-2018)
11.3 Allergic Rhinitis Sales Growth (2013-2018)
11.4 Pulmonary Arterial Hypertension Sales Growth (2013-2018)
11.5 Cystic Fibrosis Sales Growth (2013-2018)
11.6 Others Sales Growth (2013-2018)
12 Pulmonary Drugs Market Forecast (2018-2023)
12.1 Global Pulmonary Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Pulmonary Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Pulmonary Drugs Market Forecast (2018-2023)
12.2.2 Europe Pulmonary Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Pulmonary Drugs Market Forecast (2018-2023)
12.2.4 South America Pulmonary Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Pulmonary Drugs Market Forecast (2018-2023)
12.3 Pulmonary Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Pulmonary Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Pulmonary Drugs Market Share Forecast by Type (2018-2023)
12.4 Pulmonary Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Pulmonary Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Pulmonary Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Pulmonary Drugs Picture
Table Product Specifications of Pulmonary Drugs
Figure Global Sales Market Share of Pulmonary Drugs by Types in 2017
Table Pulmo
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
